SecBot SecBot
PRESS-RELEASE ·Filed Mar 25, 2026

EDAP

EDAP TMS S.A.
MIXED
Impact 6/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Monitor HIFU revenue execution against 2026 guidance; assess whether growing system placements and procedures can offset continued non-core business decline and improve profitability. Watch cash burn and potential need for financing.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.71
T+0 close · Mar 25, 2026 · via day close
Latest settled
+29.65%
T+60 · $4.81
Vs SPY
+16.19%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 25 $3.71entry
  2. T+1 · 8mo ago +1.62%α +3.39% · $3.77
  3. T+5 · 8mo ago −4.85%α −4.61% · $3.53
  4. T+20 · 7mo ago −11.32%α −19.18% · $3.29
  5. T+60 · 5mo ago +29.65%α +16.19% · $4.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

EDAP reported record full-year 2025 HIFU revenue with 39% YoY growth, driven by strong Focal One system sales and a 28% increase in U.S. procedures. However, total company revenue declined 3% YoY due to a significant drop in non-core ESWL and distribution businesses. The company posted a wider net loss of $29.2 million and reduced cash reserves, though it reiterated strong 2026 HIFU revenue growth guidance of 34%-45%.

Key Financial Metrics

Revenue
$70.5M
-3.0% YoY
EPS
$-0.78
Guidance
$72.0M–$80.0M
maintained

Key Facts

  • HIFU revenue grew 39% YoY to $37.4 million in 2025, with 69% growth in Focal One system placements
  • Total company revenue declined 3% YoY to $70.5 million due to 27% drop in non-core ESWL and distribution revenue
  • Net loss widened to $29.2 million in 2025 from $20.6 million in 2024
  • Cash and equivalents dropped 31% YoY to $20.5 million
  • Gross margin improved to 42.5% despite tariff impacts and inventory reserves
  • Company reiterated 2026 HIFU revenue guidance of $50M–$54M, representing 34%–45% YoY growth

Financial Impact

HIFU segment growing strongly at 39% YoY, but overall revenue declining and losses widening; cash burn of $16.4M in operating activities

revenueepsgross_margincash_flowcash_reserves

Risk Factors

  • Continued decline in non-core businesses may pressure overall revenue and cash flow
  • Widening net losses and declining cash reserves raise sustainability concerns
  • Execution risk in maintaining HIFU growth momentum and achieving 2026 guidance

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3262097

US Market Status

Market Closed · Opens Wed (9h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 25, 2026